electroCore Expands Intellectual Property Portfolio
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced the issuance of five new U.S. patents by the USPTO between December 17, 2024, and December 31, 2024.
These patents include:
- US Patent No. 12,168,128 - Issued on December 17, 2024, it covers systems and methods for treating medical conditions by transmitting electrical impulses to the trigeminal nerve, controlled via a mobile device.
- US Patent No. 12,168,121 - Also issued on December 17, 2024, it relates to treating developmental disorders in fetuses by delivering electrical impulses to a nerve in pregnant women.
- US Patent No. 12,172,015 - Issued on December 24, 2024, it involves a medical device generating electrical impulses and using a smart card for refilling the device after specific usage.
- US Patent No. 12,172,016 - Issued on December 24, 2024, it pertains to non-invasive vagal nerve stimulation for treating Parkinson's disease.
- US Patent No. 12,179,012 - Issued on December 31, 2024, it describes a device for non-invasive nerve stimulation, transmitting electrical impulses through the skin to a target nerve.
These patents enhance electroCore's intellectual property portfolio, potentially strengthening its market position in bioelectronic medicine.
electroCore (Nasdaq: ECOR), un'azienda bioelettronica in fase commerciale, ha annunciato l'emissione di cinque nuovi brevetti statunitensi da parte dell'USPTO tra il 17 dicembre 2024 e il 31 dicembre 2024.
Questi brevetti includono:
- Brevetto USD No. 12,168,128 - Emesso il 17 dicembre 2024, copre sistemi e metodi per trattare condizioni mediche trasmettendo impulsi elettrici al nervo trigeminale, controllabili tramite un dispositivo mobile.
- Brevetto USD No. 12,168,121 - Emesso anch'esso il 17 dicembre 2024, riguarda il trattamento di disturbi dello sviluppo nei feti mediante l'erogazione di impulsi elettrici a un nervo nelle donne in gravidanza.
- Brevetto USD No. 12,172,015 - Emesso il 24 dicembre 2024, coinvolge un dispositivo medico che genera impulsi elettrici e utilizza una smart card per il riempimento del dispositivo dopo un uso specifico.
- Brevetto USD No. 12,172,016 - Emesso il 24 dicembre 2024, si riferisce alla stimolazione non invasiva del nervo vago per il trattamento della malattia di Parkinson.
- Brevetto USD No. 12,179,012 - Emesso il 31 dicembre 2024, descrive un dispositivo per la stimolazione non invasiva dei nervi, che trasmette impulsi elettrici attraverso la pelle a un nervo obiettivo.
Questi brevetti arricchiscono il portafoglio di proprietà intellettuale di electroCore, potenzialmente rafforzando la sua posizione di mercato nella medicina bioelettronica.
electroCore (Nasdaq: ECOR), una empresa comercial de medicina bioelectrónica y bienestar, anunció la emisión de cinco nuevas patentes estadounidenses por parte de la USPTO entre el 17 de diciembre de 2024 y el 31 de diciembre de 2024.
Estas patentes incluyen:
- Patente de EE. UU. No. 12,168,128 - Emitida el 17 de diciembre de 2024, cubre sistemas y métodos para tratar condiciones médicas mediante la transmisión de impulsos eléctricos al nervio trigémino, controlados a través de un dispositivo móvil.
- Patente de EE. UU. No. 12,168,121 - También emitida el 17 de diciembre de 2024, se relaciona con el tratamiento de trastornos del desarrollo en fetos mediante la entrega de impulsos eléctricos a un nervio en mujeres embarazadas.
- Patente de EE. UU. No. 12,172,015 - Emitida el 24 de diciembre de 2024, implica un dispositivo médico que genera impulsos eléctricos y usa una tarjeta inteligente para recargar el dispositivo después de un uso específico.
- Patente de EE. UU. No. 12,172,016 - Emitida el 24 de diciembre de 2024, se refiere a la estimulación del nervio vago no invasiva para tratar la enfermedad de Parkinson.
- Patente de EE. UU. No. 12,179,012 - Emitida el 31 de diciembre de 2024, describe un dispositivo para la estimulación no invasiva de nervios, que transmite impulsos eléctricos a través de la piel a un nervio objetivo.
Estas patentes mejoran el portafolio de propiedad intelectual de electroCore, potencialmente fortaleciendo su posición en el mercado de la medicina bioelectrónica.
electroCore (Nasdaq: ECOR)는 상업 단계의 생체 전자 의학 및 웰니스 회사로서, 2024년 12월 17일부터 2024년 12월 31일 사이에 USPTO에 의해 5개의 새로운 미국 특허가 발급되었음을 발표했습니다.
이 특허에는 다음이 포함됩니다:
- 미국 특허 번호 12,168,128 - 2024년 12월 17일에 발급된 이 특허는 모바일 장치를 통해 제어되는 삼차신경에 전기 임펄스를 전달하여 의학적 상태를 치료하는 시스템과 방법을 다룹니다.
- 미국 특허 번호 12,168,121 - 2024년 12월 17일에 발급된 이 특허는 임신한 여성의 신경에 전기 임펄스를 전달하여 태아의 발달 장애를 치료하는 것과 관련이 있습니다.
- 미국 특허 번호 12,172,015 - 2024년 12월 24일에 발급된 이 특허는 전기 임펄스를 생성하는 의료 기기를 포함하며, 특정 사용 후 기기를 리필하기 위한 스마트 카드를 사용합니다.
- 미국 특허 번호 12,172,016 - 2024년 12월 24일에 발급된 이 특허는 파킨슨병을 치료하기 위한 비침습적 미주 신경 자극에 관련이 있습니다.
- 미국 특허 번호 12,179,012 - 2024년 12월 31일에 발급된 이 특허는 피부를 통해 목표 신경에 전기 임펄스를 전달하여 비침습적으로 신경 자극을 수행하는 기기를 설명합니다.
이 특허들은 electroCore의 지적 재산 포트폴리오를 강화하며, 생체 전자 의학 분야에서의 시장 위치를 잠재적으로 강화할 수 있습니다.
electroCore (Nasdaq: ECOR), une entreprise de médecine bioélectronique et de bien-être commercialement active, a annoncé l'octroi de cinq nouveaux brevets américains par l'USPTO entre le 17 décembre 2024 et le 31 décembre 2024.
Ces brevets comprennent :
- Brevets US n° 12,168,128 - Délivré le 17 décembre 2024, il couvre des systèmes et méthodes pour traiter des conditions médicales en transmettant des impulsions électriques au nerf trijumeau, contrôlées via un appareil mobile.
- Brevets US n° 12,168,121 - Également délivré le 17 décembre 2024, il concerne le traitement des troubles du développement chez les fœtus par la transmission d'impulsions électriques à un nerf chez les femmes enceintes.
- Brevets US n° 12,172,015 - Délivré le 24 décembre 2024, il implique un dispositif médical générant des impulsions électriques et utilisant une carte intelligente pour recharger le dispositif après une utilisation spécifique.
- Brevets US n° 12,172,016 - Délivré le 24 décembre 2024, il concerne une stimulation non invasive du nerf vague pour traiter la maladie de Parkinson.
- Brevets US n° 12,179,012 - Délivré le 31 décembre 2024, il décrit un dispositif de stimulation nerveuse non-invasive, transmettant des impulsions électriques à travers la peau à un nerf cible.
Ces brevets renforcent le portefeuille de propriété intellectuelle d'electroCore, ce qui pourrait potentiellement renforcer sa position sur le marché de la médecine bioélectronique.
electroCore (Nasdaq: ECOR), ein biomedizinisches Unternehmen im kommerziellen Stadium, hat die Ausstellung von fünf neuen US-Patenten durch das USPTO zwischen dem 17. Dezember 2024 und dem 31. Dezember 2024 angekündigt.
Diese Patente umfassen:
- US-Patent Nr. 12,168,128 - Ausgestellt am 17. Dezember 2024, deckt es Systeme und Methoden zur Behandlung medizinischer Zustände ab, indem elektrische Impulse an den Trigeminusnerv übertragen werden, die über ein Mobilgerät gesteuert werden.
- US-Patent Nr. 12,168,121 - Ebenfalls am 17. Dezember 2024 ausgestellt, bezieht sich dies auf die Behandlung von Entwicklungsstörungen bei Föten durch die Abgabe elektrischer Impulse an einen Nerv bei schwangeren Frauen.
- US-Patent Nr. 12,172,015 - Ausgestellt am 24. Dezember 2024, betrifft es ein medizinisches Gerät zur Erzeugung elektrischer Impulse und verwendet eine Smart Card zur Nachfüllung des Geräts nach spezifischer Verwendung.
- US-Patent Nr. 12,172,016 - Ausgestellt am 24. Dezember 2024, bezieht sich dies auf nicht invasive Vagusnervstimulation zur Behandlung der Parkinson-Krankheit.
- US-Patent Nr. 12,179,012 - Ausgestellt am 31. Dezember 2024, beschreibt es ein Gerät zur nicht invasiven Nervenstimulation, das elektrische Impulse durch die Haut an einen Zielnerv überträgt.
Diese Patente erweitern das geistige Eigentumsportfolio von electroCore und könnten die Marktposition im Bereich der bioelektronischen Medizin potenziell stärken.
- Five new U.S. patents granted between December 17, 2024, and December 31, 2024, enhancing the intellectual property portfolio.
- Patents cover a range of innovative medical treatments, including non-invasive nerve stimulation and devices for treating Parkinson's disease and developmental disorders.
- None.
Insights
This patent portfolio expansion significantly strengthens electroCore's market position in bioelectronic medicine. The newly granted patents cover critical technological aspects: mobile-controlled nerve stimulation, fetal developmental treatment, device refill systems, Parkinson's disease treatment and precise nerve stimulation protocols.
The "refillable" medical device patent (US 12,172,015) is particularly valuable as it creates a recurring revenue model similar to prescription medications. This could transform the company's business model from one-time device sales to ongoing treatment subscriptions. The mobile device integration patent (US 12,168,128) aligns with digital health trends and enables remote treatment management.
The fetal development and Parkinson's disease patents significantly expand the addressable market beyond current indications, potentially opening new revenue streams worth billions in these underserved therapeutic areas.
The breadth of these patents creates substantial barriers to entry in the non-invasive neuromodulation space. The technical specifications, particularly the 800-2,000 microsecond burst durations and 1-20 kHz frequency ranges, are precisely defined to optimize therapeutic efficacy while maintaining safety profiles.
The mobile integration capability positions electroCore ahead of competitors by enabling precise dosage control and compliance monitoring - essential features for insurance reimbursement. The RFID/smart card refill system is ingenious, allowing usage-based billing while preventing unauthorized use.
Think of these patents as building blocks that combine into a comprehensive treatment platform, similar to how a smartphone ecosystem integrates hardware, software and services. This positions electroCore to potentially become the "Apple of bioelectronics" with a controlled, integrated treatment ecosystem.
electroCore Granted Five New U.S. Patents
ROCKAWAY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received five patent issue notifications from the United States Patent and Trademark Office (USPTO). The five patents have been issued between December 17, 2024, and December 31, 2024:
- US Patent No. 12,168,128 entitled “Systems and Methods for Treating a Medical Condition” was issued on December 17, 2024, and generally relates to a stimulator transmitting electrical impulses to the trigeminal nerve in the patient’s head to treat a medical condition. The stimulator is linked to a software program downloadable onto a mobile device that can control a parameter of the electrical impulse and authorize the stimulator to transmit the electrical impulse.
- US Patent No. 12,168,121 entitled “Devices and Methods for Treating or Preventing Developmental Disorders” was issued on December 17, 2024, and generally relates to a method for treating a developmental condition or disorder in a fetus of a pregnant woman by delivering an electrical impulse having a frequency range of about 1 kHz to about 20 kHz to a nerve within a woman.
- US Patent No. 12,172,015 entitled “Systems and Methods for Initial Provisioning and Refilling of Medical Devices” was issued on December 24, 2024, and generally relates to a medical device configured to generate electrical impulses for a period of time or a single dose, and a processor configured to interface with a storage medium, such as an RFID card, barcode, QR code or the like, to erase or scramble the card after a specific number of single doses have been applied by the device (i.e., a medical device that can be “refilled” for further use with a smart card).
- US Patent No. 12,172,016 entitled “Non-Invasive Electrical Stimulation for Medical Disorders” was issued on December 24, 2024, and generally relates to systems and methods for treating Parkinson’s disease with non-invasive vagal nerve stimulation.
- US Patent No. 12,179,012 entitled “Devices and Methods for Non-Invasive Nerve Stimulation” was issued on December 31, 2024, and generally relates to a device and method for treating a disorder in a patient. The device comprises a housing and an energy source configured to generate an electrical impulse and transmit the electrical impulse through an outer skin surface to a target nerve within the patient. The electrical impulse comprises bursts of alternating pulses with each burst having a duration of about 800 to about 2,000 microseconds.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What new patents did electroCore (ECOR) receive in December 2024?
How do the new patents impact electroCore's intellectual property portfolio?
What conditions are targeted by electroCore's new patents?
When were the new patents for electroCore (ECOR) issued?
What type of technologies are covered by electroCore's new patents?
